FOSAMPRENAVIR Drug Patent Profile
✉ Email this page to a colleague
When do Fosamprenavir patents expire, and when can generic versions of Fosamprenavir launch?
Fosamprenavir is a drug marketed by Mylan and Sun Pharm and is included in two NDAs.
The generic ingredient in FOSAMPRENAVIR is fosamprenavir calcium. There are four drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the fosamprenavir calcium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Fosamprenavir
A generic version of FOSAMPRENAVIR was approved as fosamprenavir calcium by MYLAN on April 15th, 2016.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for FOSAMPRENAVIR?
- What are the global sales for FOSAMPRENAVIR?
- What is Average Wholesale Price for FOSAMPRENAVIR?
Summary for FOSAMPRENAVIR
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Drug Prices: | Drug price information for FOSAMPRENAVIR |
| DailyMed Link: | FOSAMPRENAVIR at DailyMed |
US Patents and Regulatory Information for FOSAMPRENAVIR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mylan | FOSAMPRENAVIR CALCIUM | fosamprenavir calcium | TABLET;ORAL | 204060-001 | Apr 15, 2016 | AB | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Sun Pharm | FOSAMPRENAVIR CALCIUM | fosamprenavir calcium | TABLET;ORAL | 204024-001 | Nov 20, 2019 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
